Septerna - 1781718 - SEPTERNA INC
Explicit Guidance:
- SCP-479 (Hyperparathyroidism): Phase 1 trial readout expected in Q1 2027; Phase 2 trials targeted for second half of 2026; chronic toxicology studies to precede Phase 2 initiation to enable open-label extensions for Phase 3 patients.
- SCP-204 (Graves' Disease/Thyroid Eye Disease): Phase 1 clinical initiation scheduled for Q1 2027; healthy volunteer data anticipated prior to end of 2027.
- Novo Collaboration: First development candidate selected for advancement from the 5-target, 4-program portfolio established in mid-2025.
- Clinical Endpoints (Phase 1 Targets):
- SCP-479: Target endogenous PTH reduction of ~50% and serum calcium increase of ~0.5 mg/dL (starting dose) up to ~1.0 mg/dL (high dose).
- SCP-204: Target endogenous TSH increase and suppression of thyroid hormones at high doses.
- Project Half-Life Projections:
- SCP-479: Actual human half-life observed at 3–4 days (vs. projected 40–80 hours); Urovipath (competitor) simulated half-life ~2.5 days.
- SCP-204: Projected human half-life of 20–40 hours to support once-daily dosing.
Business-Segment Outlook:
- SCP-479 (PTH1R Agonist): Positioning as an oral alternative to daily injectable peptides (e.g., Urovipath) to expand treatable population beyond severe patients to include moderate cases; potential for broader patient access due to lack of need for intact parathyroid tissue (unlike Encalerate).
- SCP-204 (TSHR Antagonist): Dual target for Graves' disease and Thyroid Eye Disease (TED); potential for dose optionality to either normalize thyroid function or fully suppress it.
- SCP-631 (MRG-Perox-2): Strategy shifting from large Phase 2 in Chronic Spontaneous Urticaria (CSU) to smaller, signal-finding studies to identify high-probability indications including migraine, interstitial cystitis, and asthma.
- OSTEOPOROSIS PROGRAM: Developing a second PTH agonist distinct from SCP-479; requires a short-acting compound (anabolic effect) vs. the long-acting nature of the hyperparathyroidism drug.
- NOVO PARTNERSHIP: Collaboration on 5 targets is advancing; Novo selected the first development candidate and plans to move it forward.
Market and Competitive Outlook:
- Hyperparathyroidism Landscape: Addressing 70,000–80,000 U.S. patients; current standard of care (calcium/Vitamin D) considered suboptimal; Urovipath (injectable) is the current benchmark for peptide replacement.
- Competitive Differentiation: Differentiation from Encalerate (calcium-sensing receptor agonist) based on mechanism; Encalerate requires intact parathyroid tissue (unavailable in post-surgical patients), whereas SCP-479 provides direct PTH replacement.
- Mast Cell Program (X2/SCP-631): Exploring migraine as a key indication due to emerging data on mast cell activation and neuropeptide (PACAP) involvement; aiming for "best-in-class" profile via negative allosteric modulation.
Macro / Industry Outlook:
- Regulatory/Development Strategy: Leveraging healthy volunteer data for proof-of-concept in rare diseases (hyperparathyroidism, Graves') based on the premise that receptor biology is consistent between healthy volunteers and patients.
- Pricing Strategy: No explicit pricing guidance provided; focus remains on demonstrating patient benefit over existing therapies before pricing discussions.
Strategic Initiatives:
- Oral Small Molecule Platform: Continued refinement of the "Native Complex Platform" to enable oral small molecules that mimic peptide functionality for difficult GPCR targets.
- Clinical Trial Design: Implementing titration protocols in Phase 2 to mimic injectable peptide precedents (dosing up drug while down-titrating calcium/Vitamin D supplements).
- Pipeline Expansion: Moving from single-indication focus to broader signal-finding for mast cell targets (migraine, asthma, interstitial cystitis).
Risks and Headwinds to Outlook:
- Mechanism Specificity: Encalerate's potential success in post-surgical patients remains uncertain pending Phase 3 data; SCP-479 relies on full PTH replacement which may be viewed differently by payers vs. calcium-balancing agents.
- Safety Signals: SCP-204 preclinical GLP toxicology showed signs of exaggerated on-target pharmacology (hypothyroidism), which must be managed in clinical dosing.
- Development Timelines: Delays in chronic toxicology studies or unexpected Phase 1 readouts could impact the 2026/2027 Phase 2 start targets.
- Competitive Uncertainty: Unknown efficacy of Encalerate in the specific post-surgical population; potential for other oral competitors to emerge.
Management Tone on the Future:
- Confidence: High confidence in the platform's ability to solve historical difficulties in creating oral small molecules for GPCRs (PTH1R, TSHR).
- Optimism: Describing SCP-479 and SCP-204 as having "great activity" and "best-in-class profile" potential; expressing excitement about the Novartis collaboration progress.
- Strategic Shift: Willingness to pivot from large CSU studies for SCP-631 to smaller, faster signal-finding studies for migraine and other indications.
Miscellaneous:
- Trial Locations: SCP-479 Phase 1 conducted in Australia.
- Biomarkers: Expectation of endocrine feedback loops to drive biomarker changes (PTH down/Calcium up for SCP-479; TSH up/Thyroid hormones down for SCP-204).
- Company
- SEPTERNA INC
- Keywords
- SEPTERNA INC